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Available online 15 January 2016Engagement of the T cell receptor complex reprograms T cells for proliferation, cytokine production and differen-
tiation towards effector cells. This process depends on activating costimulatory signals and is counteracted by
coinhibitory molecules. Three transcription factors, namely NF-κB, NFAT and AP-1, have a major role in inducing
the transcriptional program that is required for T cell activation and differentiation. Here we describe the gener-
ation of a triple parameter reporter based on the human Jurkat T cell line, where response elements for NF-κB,
NFAT and AP-1 drive the expression of the ﬂuorescent proteins CFP, eGFP and mCherry, respectively. The emis-
sion spectra of these proteins allow simultaneous assessment of NF-κB, NFAT and AP-1 activity in response to
stimulation. Ligation of the TCR complex induced moderate reporter activity, which was strongly enhanced
upon coengagement of the costimulatory receptors CD2 or CD28. Moreover, we have generated and tested triple
parameter reporter cells that harbor costimulatory and inhibitory receptors not endogenously expressed in the
Jurkat cells. In these experimentswe could show that engagement of the costimulatorymolecule 4-1BB enhances
NF-κB and AP-1 activity, whereas coinhibition via PD-1 or BTLA strongly reduced the activation of NF-κB and
NFAT. Engagement of BTLA signiﬁcantly inhibited AP-1, whereas PD-1 had little effect on the activation of this
transcription factor. Our triple parameter reporter T cell line is an excellent tool to assess the effect of
costimulatory and coinhibitory receptors on NF-κB, NFAT and AP-1 activity and has a wide range of applications
beyond the evaluation of costimulatory pathways.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Reporter-assay1. Introduction
T cell responses play a key role in adaptive immunity and it is there-
fore of crucial importance to understand how external signals modulate
the intracellular T cell signaling machinery. Engagement of the TCR–
CD3 complex and the coreceptors CD4 and CD8 are regarded as the
main trigger to turn on T cells. Activation and nuclear translocation of
transcription factors are amajor downstream consequence of TCR signal-
ing. These molecular events eventually lead to reprogramming of T cells
for proliferation and differentiation in order to acquire a speciﬁc effectorhycocyanin; CsA, Cyclosporin A;
otein; gMFI, geometric mean of
FAT-interacting protein; RE, re-
rameter reporter.
, Center for Pathophysiology,
ienna, Lazarettgasse 19, 1090
P. Steinberger).
. This is an open access article underphenotype. The three transcription factors NF-κB, NFAT and AP-1 play an
important role in T cell activation processes (Crabtree and Clipstone,
1994). NF-κB is a dimer composed of the NF-κB family members RELA,
RELB, cREL, p100/52 andp105/p50. Together, they formhomo- or hetero-
dimers, usually of RELA and p50 or p52, inducing transcription of NF-κB
dependent genes for survival, proliferation and cytokine production (Li
and Verma, 2002). The NFAT family consists of ﬁve members with a
REL-homology region for DNA binding and is widely expressed in differ-
ent cell types. Four of theﬁveNFAT proteins are regulated by intracellular
Ca2+ signaling. NFAT activation upon TCR signaling, autoregulation or cy-
tokine receptor signaling results in translocation into the nucleus and ex-
pression of cytokines such as IL-2 (Macian, 2005). In the nucleus, NFAT
cooperates with other transcription factors, mainly AP-1 (Jain et al.,
1992), a dimeric proteinwhich is expressed inmany cell types and differ-
entially composed of the subfamilies c-Jun, Fos, Maf and ATF, with c-Jun
being the most potent activator of transcription among these molecules.
Stimuli such as TCR triggering activate AP-1 thereby promoting differen-
tiation, survival and proliferation of cells (Shaulian and Karin, 2002).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cells that present their cognate antigen can potently modulate TCR-
signals and thus enhance or attenuate the activity of NF-κB, NFAT and
AP-1. So-called second signals, which are generated by the interaction
of the T cell-expressed costimulatory receptors with their correspond-
ing membrane-bound ligands, are arguably the most important
among these accessory signals. Receptor–ligand pairs belonging to dif-
ferent molecule families have been categorized to this ever-growing
group of molecules (Chen and Flies, 2013; Leitner et al., 2010a; Watts,
2005). The individual role of many costimulatory receptors in cellular
activation processes including their impact on the transcriptional pro-
gram of T cells is currently not fully understood.
Studies on transformed T cell lines have greatly contributed to our
understanding of T cell signaling and T cell costimulatory signals in par-
ticular. The human leukemic T cell line Jurkat is probably themostwide-
ly employed model system to study T cell signaling (Abraham and
Weiss, 2004). Jurkat-based reporter systems are commonly used to ex-
plore the impact of external stimuli on the activation of transcription
factors such asNF-κB, NFAT and AP-1.Most of the reporter lines only ac-
count for one, maximally two signaling pathways simultaneously
(Magness et al., 2004; Noguchi et al., 2008), and thus in most cases
the use of different reporters is necessary to get insight into the capacity
of agents to trigger or inhibit distinct activation programs (Ratzinger
et al., 2014). Herewe report on the generation of a Jurkat-based reporter
system that enables to measure simultaneously and independently the
activity of NF-κB, NFAT andAP-1.Moreover,we have assessed the utility
of this reporter line to study the impact of costimulatory and
coinhibitory pathways on the activation of these transcription factors.
2. Materials and methods
2.1. Antibodies, cell culture and ﬂow cytometry
Bw5147 (short designation within this work Bw) and the Jurkat T
cell line JE6.1 were cultured as described previously (Pﬁstershammer
et al., 2006; Derdak et al., 2006).
To conﬁrm surface expression of the indicated molecules expressed
on T cell stimulator cells (TCS) and Jurkat reporter cell lines, the following
PE-conjugated mAbs were used: CD58 (TS2/9), CD80 (2D10), PD-L1
(29E.2A3), 4-1BBL (5F4), HVEM (TR2), PD-1 (EH12.2H7), 4-1BB (4B4-
1), BTLA (MIH26) and appropriate isotype control, all purchased from
BioLegend (San Diego, CA). Expression of a membrane-bound anti-CD3-
antibody-fragment on the surface of the T cell stimulator cellswas detect-
ed via DyLight-649-conjugated goat-anti-mouse IgG (H + L) antibody
(Jackson ImmunoResearch, West Grove, PA) as described previously
(Leitner et al., 2010b). In coculture experiments where reporter cells
were stimulated with T cell stimulator cells, a mouse (m)CD45.2-APC
(clone 104, BioLegend) was used to exclude the T cell stimulator cells
from the FACS analyses. Flow cytometric analysis was performed using
a LSRFORTESSA ﬂow cytometer (Becton Dickinson Immunocytometry
System, CA) supported by FACS Diva software. Data was analyzed using
the FlowJo software (version 10.0.6., Tree Star, Ashland, OR). Fluores-
cence intensity is shown on a standard logarithmic scale. Functional
grade CD28 (clone 28.2, BioLegend), functional grade CD2 (clone TS1/8,
BioLegend), functional grade PD-L1 (5 μg/ml ﬁnal concentration, clone
29E.2 A3, BioLegend), polyclonal HVEM (8 μg/ml ﬁnal concentration,
R&D Systems, Minneapolis, MN), CD3 (OKT3, Ortho Pharmaceutical
Corp., Raritan, NJ), CD63 (clone 11C9, produced in our laboratory) or
CD28 Superagonist (2 μg/ml ﬁnal concentration, ANC28.1/5D10, Ancell
Bayport, MN) antibodies were used to stimulate reporter cells.
2.2. Design of reporter constructs
A self-inactivating retroviral vector encoding a NF-κB-eGFP reporter
construct (pSIRV-NF-κB-eGFP) was described previously (Platzer et al.,
2004). The construct contains a response element (RE) for NF-κB, aminimal promoter (MP) and eGFP as reporter gene. The construct was
modiﬁed through removal of a fragment corresponding to the 5' end
of a luciferase gene. For this, a part of the minimal promoter and eGFP
was PCR-ampliﬁed with primers omitting the partial luciferase se-
quence. EcoRI and NotI restriction sites were added to the ends of the
primers. The PCR product was cloned into the reporter vector and the
integrity of the construct was conﬁrmed by DNA sequencing.
For the construction of amodular system, the cassette containing the
response element (RE) for NF-κB, minimal promoter and eGFP was
modiﬁed. Using the original construct as a template and multiple over-
lapping primers, PCR products containing the NF-κB, the minimal pro-
moter (MP) and eGFP were generated and fused by overlap extension
PCR. The PCR primers contained unique restriction sites to generate a
cassette (BamHI–NF-κB-RE–EcoRI–MP–HindIII–eGFP–NotI) where the
individual parts could easily be replaced. The integrity of the cassette
was conﬁrmed by DNA sequencing.
Cyan ﬂuorescent protein (CFP) was cloned from pCAG-CFP
(Matsuda and Cepko, 2004) (pCAG-CFP was a gift from Connie Cepko,
Addgene plasmid # 11179) using primers containing HindIII and NotI
restriction sites. Subsequently, eGFP in theNF-κB-eGFP-reporterwas re-
placed with CFP to obtain an NF-κB-CFP reporter.
For the NFAT-eGFP reporter, a NFAT reporter construct (Schichl
et al., 2009) (a kind gift from R. de Martin) was PCR-ampliﬁed using a
primer pair with ﬂanking BamHI and EcoRI restriction sites to obtain
the NFAT-RE. Subsequently, the NF-κB-RE in the modular NF-κB-eGFP
reporter construct was replaced with the NFAT-RE.
For the AP-1-mCherry reporter, the AP-1 RE consisting of three re-
peats of two alternative AP-1 binding sites (tgactcag, tgagtcag (Angel
et al., 1987)) with ﬂanking BamHI and EcoRI restriction sites, and an al-
ternate minimal promoter with EcoRI and HindIII sites were ampliﬁed
individually using overlapping PCR Primers. The mCherry cDNA was
cloned from the pLV-mCherry plasmid (a gift from Pantelis Tsoulfas,
Addgene plasmid # 36084). To obtain the AP-1-mCherry reporter, the
minimal promoter (described by Vodjdani et al. (Vodjdani et al.,
1988)) and eGFP from the modular NF-κB-eGFP cassette were replaced
with the alternate minimal promoter and mCherry. The integrity of all
inserts was veriﬁed by DNA sequencing.
2.3. Generation of triple parameter T cell reporter cell lines and T cell stim-
ulator cells
In a ﬁrst step an ecotropic receptor (Jorgl et al., 2007) was intro-
duced into JE6.1 cells to increase transduction efﬁciency. Subsequently,
JE6 cells were transduced simultaneously with NF-κB-CFP, NFAT-eGFP
and AP-1-mCherry constructs using a previously described retroviral
transduction protocol (Steinberger et al., 2004). Single cell clones
were established from the transduced cell pool and screened for low-
absent expression of reporter genes in a resting state and strong upreg-
ulation of eGFP, mCherry and CFP upon stimulation with PMA/
Ionomycin. A cell clone fulﬁlling these criteria was selected and termed
triple parameter reporter (short designation in this work: TPR cells).
Sequences encoding PD-1, 4-1BB and BTLA cloned from a human T
cell cDNA library (Popow et al., 2013) were introduced in the retroviral
expression vector pCJK2 and integrity of the resultant constructs was
conﬁrmed by DNA sequencing. Subsequently, the TPR cells were
retrovirally transduced with these constructs, and single cell clones ex-
pressing human 4-1BB, PD-1 or BTLA were established.
For the knockdown experiments, oligonucleotides for shRNA-
sequences from the RNAi Consortium for NF-κB1 (accession numbers
TRCN0000006518, TRCN0000006520), NFATc3 (accession numbers
TRCN0000014529, TRCN0000014529) and AP-1 (accession numbers
TRCN0000016004, TRCN0000016007) were introduced in the lentiviral
vector Tet-pLKO-puro (Wiederschain et al., 2009) (a gift from Dimitri
Wiederschain, Addgene plasmid # 21915). The integrity of the con-
structs was conﬁrmed by DNA sequencing, followed by lentiviral trans-
duction of the TPR cells with these plasmids. Transduced cells were
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pression of shRNA was induced by adding 100 ng/ml Doxycycline for
48 h (Sigma Aldrich) and knockdown of mRNA expression was con-
ﬁrmed by real-time PCR. Real-time PCR-Data were normalized to the
mRNA levels measured in the cells expressing control shRNA.
T cell stimulator cells (short designation: TCS) have been described
previously (Leitner et al., 2010b). In brief, TCS are Bw5147 cells (murine
thymoma cell line) that have been engineered to stably express an anti-
human CD3 single chain fragment anchored to the cell membrane via a
human CD14 stem (CD5L-OKT3scFv-CD14) and thus can activate
human T cells upon coculture. These cells were retrovirally transduced
to express high levels of human CD58, CD80, PD-L1, 4-1BBL or HVEM
as described previously. Cells expressing no human costimulatory mol-
ecule were used as control TCS (TCS-ctrl). Surface expression of
membrane-bound anti-CD3 and the costimulatory ligands was con-
ﬁrmed by FACS analysis (Leitner et al., 2010b; Kober et al., 2008).
2.4. Stimulation experiments and reporter assays
Triple parameter reporter cells (5 × 104/well) were either cocultured
with T cell stimulator cells (5 × 103/well) or stimulatedwith plate-bound
antibodies in 96-well ﬂat bottom plates for 24 h, unless indicated other-
wise. For plate-bound assays CD3 antibodies (ﬁnal concentration as
indicated) were coated at 4 °C overnight in conjunction with either
isotype control, CD28, CD2 or CD63 mAb (each at a ﬁnal concentration
of 2 μg/ml), as described in detail (Leitner et al., 2009).
In some experiments, PMA, Ionomycin (each 100 nM, Sigma
Aldrich) or Cyclosporin A (CsA, Sandimmun®, Switzerland, used at indi-
cated ﬁnal concentrations) were added.
Following 24hof stimulation, cellswere harvested and cocultures of re-
porter cellswith TCSwere stainedwith anAPC-labeled anti-murine CD45.2
mAb to exclude the APC-positive cells (TCS) from the analysis. Subsequent-
ly, expressionof eGFP, CFP andmCherryweremeasuredbyﬂowcytometry.
Mean and standard deviation of the geometricmean of ﬂuorescence inten-
sity (gMFI) of the whole population of viable reporter cells identiﬁed ac-
cording to their forward and side-scatter properties were determined from
duplicate wells. Transcription factor activity upon activation was calculated
by normalizing to the gMFI of the unstimulated control (fold induction).
For the knockdown experiment, the fold induction of the reporter
ﬂuorophore in the target shRNA expressing cells was normalized to
the fold induction measured in the cells containing the control shRNA.
2.5. Microscopy
Unstimulated TPR cells and TPR cells stimulated for 24 h with PMA
and Ionomycin (each 100 nM ﬁnal concentration) were washed and di-
rectly recorded in PBS at 25 °C. Image acquisition was performed with a
Leica DMI4000B microscope (Leica Microsystems; Wetzlar, Germany)
equipped with a 100× immersion objective (Leica HCX PL Apo 100×,
NA1.47) and anAndor iXonUltra-8871 EM-CCD camera (Andor Technol-
ogies; Belfast, UK), controlled by the Leica Application Suite Advanced
Fluorescence software (versionAF6000LX).mCherry excitation and emis-
sion light ﬁltering was done using TRITC conﬁguration of Leica Quad-
Sedat ﬁlter system (set 11532564). To avoid crosstalk of CFP and eGFP,
the Leica CFP/YFP FRET ﬁlter system (set 11522073) was used, with
eGFP being recorded in YFP conﬁguration. Image analysis was performed
with ImageJ open source software (Version 1.48, National Institute of
Health, Washington, DC).
2.6. Statistics
Means from duplicate wells and +/−SD are shown. Using GraphPad
Prism (Version 5, GraphPad Software, Inc., La Jolla, CA), data were ana-
lyzed by two-sided paired t-test, one-way analysis of variance (ANOVA)
followed by Turkey posthoc tests or two-way ANOVA followed by
Bonferroni post tests (ns not signiﬁcant, *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001).3. Results
3.1. Generation of a triple parameter reporter T cell line
The transcription factors NF-κB, NFAT and AP-1 play essential roles in
the activation of T cells. Our goalwas to establish a reporter T cell line en-
abling the measurement of the activity of those three transcription fac-
tors simultaneously and to use it for the investigation of costimulatory
and inhibitorymolecules. In aﬁrst step,we generated amodular reporter
cassette where transcription factor response elements, minimal promot-
er sequences and reporter genes can easily be exchanged. Constructs
harboring different combinations of responsive elements and minimal
promoters were introduced into the human T cell line Jurkat E6.1 and
combinations that yielded optimal reporter gene induction were chosen
for further use (data not shown). Subsequently, we generated reporter
constructs where the selected responsive elements for NF-κB, NFAT
and AP-1 were combined with sequences encoding CFP, eGFP and
mCherry, respectively (Fig. 1 A). Jurkat cells were transducedwith retro-
viral constructs containing these three reporters and a large panel of cell
clones was established from the resulting cell pool. A single cell clone
that showed high induction of all three reporter genes upon activation
with PMA and Ionomycin was selected for further use (Fig. 1 B, C) and
was designated triple parameter reporter (short designation within
this work TPR cells).
In a next step,we analyzed the reporter activity in our TPR cells upon
TCR-complex engagement in absence or presence of costimulatory sig-
nals to validate our system. For this,we used T cell stimulator cells (TCS)
that carry a membrane-bound anti-CD3 antibody fragment and thus
generate signal 1 in T cells (Leitner et al., 2010b). In addition to TCS
that do not express costimulatory ligands (TCS-control) we used TCS
expressing the costimulatory ligands human CD80 (TCS-CD80) or
CD58 (TCS-CD58) to trigger the costimulatory receptors CD28 and
CD2, respectively (Fig 1 D). Coculture of the reporter cells with control
TCS resulted in a moderate expression of all three reporter genes,
whereas TCS expressing CD80 or CD58 strongly enhanced transcription-
al activity of NF-κB, NFAT and AP-1 (Fig. 1 E, F).
Of note, while engagement of CD28 (via CD80) led to a signiﬁcantly
stronger NF-κB activation compared to CD2-CD58 stimulation, the dif-
ference in NFAT and AP-1 activation was not signiﬁcant (Fig. 1 G). Com-
bined, these results demonstrate that our TPR cell line is both a robust
and precise tool to assess transcription factor activity by means of re-
porter gene expression upon delivery of signal 1. Moreover, a marked
up-regulation of reporter proteins can be measured in the reporter
cells when signal 2 is provided in addition to signal 1.
3.2. Kinetics of NF-κB, NFAT and AP-1 activation
We performed time course stimulation experiments to compare the
kinetics of NF-κB, NFAT and AP-1 activity and to determine the time re-
quired for maximal activation. For strong costimulation we employed
TCS expressing CD80. TPR cells were cocultivated with stimulator
cells, harvested at different time points and subsequently analyzed by
FACS. While AP-1 activity peaked already at the 8-h time point, NF-κB
activity reached its maximum after 24 h. Activation was slowest for
NFAT with the highest reporter expression measurable after 72 h. At
this time point NF-κB and AP-1 activity was already declining (Fig. 2).
3.3. Effects of PMA, Ionomycin and Cyclosporin A
In a next set of experiments, we assessed the impact of PMA,
Ionomycin and Cyclosporin A (CsA) on the TPR cells. The phorbol ester
PMA is described to activate protein kinase C and consequently AP-1
and NF-κB (Khalaf et al., 2010). The ionophore Ionomycin leads to an in-
crease in cytoplasmic Ca2+ levels, which in turn is required for the de-
phosphorylation of NFAT followed by its translocation into the nucleus
(Ruff and Leach, 1995). Therefore, TPR cells were activated with either
Fig. 1.Generation and characterization of the triple parameter reporter T cell line (TPR). A) Schematic illustration of reporter constructs encodingNF-κB CFP, NFAT eGFP and AP-1mCherry
with restriction enzyme recognition sites. MP: minimal promoter. B) Activation of TPR cells with PMA and Ionomycin to induce activation of NF-κB, NFAT and AP-1. Open histograms:
unstimulated control; ﬁlled histograms: cells stimulated with PMA and Ionomycin. C) Fluorescent microscopy images of TPR cells activated with PMA and Ionomycin (lower panel).
Unstimulated cells served as negative control (upper panel). D) FACS analysis of the expression of surface molecules on T cell stimulator cells (TCS). Open histograms: control cells;
ﬁlled histograms: control TCS or TCS coexpressing CD58 or CD80. E) Histogram and F) dot plot representation of reporter assays to measure the effect of CD58 and CD80 on the
transcription factor activity of NF-κB, NFAT and AP-1. TPR cells were cocultivated with TCS expressing CD58 or CD80 for 24 h. Activation of NF-κB, NFAT and AP-1 were measured by
FACS analysis. Numbers show geometric mean of ﬂuorescence intensity (gMFI). Experiment shown is representative for 5 independently performed experiments. G) Summary of the
normalized fold induction of gMFI of the TPR cells compared to unstimulated cells from ﬁve independent experiments. Statistics by one-way ANOVA, followed by Tukey's multiple
comparison post test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns: not signiﬁcant).
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FACS analysis of reporter gene expression. Treatment with PMA alone
strongly induced the activation of NF-κB and AP-1 reporters, but did not
induce NFAT activity as expected. Ionomycin alone did not change tran-
scriptional activity of NF-κB, AP-1 and it was also ineffective in upregula-
tion of NFAT activity. A strong upregulation of theNFAT reporterwas only
observedwhen Ionomycinwas added in combinationwith PMA. This is in
linewith previous reports that demonstrate that additional stimuli are re-
quired to induce NFAT activity upon Ionomycin treatment of Jurkat cells
(Boss et al., 1996; Northrop et al., 1993; Wu et al., 1995). In addition,Ionomycin further increased the PMA-induced upregulation of NF-κB
and AP-1 reporters (Fig. 3 A). These results show that the response ele-
ments of NF-κB and AP-1 are speciﬁcally bound by the respective tran-
scription factors upon addition of PMA.
The calcineurin inhibitor CsA is known to reduce the activation of
NFAT, but also that of NF-κB (Flanagan et al., 1991; Frantz et al., 1994).
The inhibitory effect of different CsA concentrations on the activation of
NF-κB, NFAT and AP-1 was analyzed in the TPR cells. To assess whether
CsA has a differential effect on the costimulatory pathways CD2-CD58
and CD28-CD80, TPR cells were cocultivated with TCS-CD58 or TCS-
Fig. 2. Kinetics of the transcription factor activity of NF-κB, NFAT and AP-1. A) TPR cells
were stimulated with TCS-CD80 for the indicated time-points. Activation of NF-κB, NFAT
and AP-1 was analyzed by FACS. Open histograms: unstimulated TPR cells; ﬁlled
histograms: TCS-CD80 activated TPR cells. Numbers show gMFI of TCS-CD80 activated
TPR cells. B) Percentage of maximum activation of NF-κB, NFAT and AP-1. Fold induction
of gMFI of the TPR cells was normalized to the highest fold induction of NF-κB, NFAT
and AP-1 in this experiment, respectively.
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centrations for 24 h. In TCS-CD80 stimulated TPR cells, transcription factor
activity of NF-κB and NFAT were signiﬁcantly reduced in the presence of
CsA at a ﬁnal concentration of 200 nM. AP-1 activity was not signiﬁcantly
inﬂuenced by CsA (Fig. 3 B, C, Suppl. Fig. 1 A).Whenwe compared the ef-
fect of CsA in reporter cells that were costimulated via CD2 or CD28, we
observed that NF-κB ismore sensitive to CsA in CD2- than in CD28 signal-
ing. In contrast, CsA-mediated inhibition of NFAT activity was not differ-
entially affected by costimulation via CD2 or CD28. (Fig. 3 D).3.4. Speciﬁcity of the responsive elements in the TPR cells
In order to further assess the speciﬁcity of the reporter constructs in
our TPR cells we used lentiviral doxycycline-inducible shRNA vectors to
knockdown NF-κB1, NFATc3 or c-Fos. Two constructs were generated
for each target gene and were introduced into the TPR cells by lentiviral
transduction. Following expansion and puromycin selection of trans-
duced cells, shRNA expression was induced by adding doxycycline,and 48 h later themRNA expressionwas assessed by qPCR. Gene silenc-
ingwas achieved for each target genewith at least one of the constructs
(Fig. 4 A, C, E). In parallel, the TPR cells were activated using CD80 ex-
pressing TCS and following 24 h of coculturing the reporter-gene ex-
pression was assessed by ﬂow cytometry. Silencing of NF-kB1, NFATc3
and c-Fos resulted in a signiﬁcant and speciﬁc reduction of the targeted
transcription factors (Fig. 4 B, D, F).
3.5. Stimulation of TPR cells with mAbs
Agonistic antibodies to the TCR–CD3 complex and to costimulatory
receptors arewidely used to activate T cells and T cell lines. Consequently
we analyzed the response of the TPR cells to CD3 antibodies and antibod-
ies to costimulatory receptors coimmobilized on ELISA-plates. In addition
to stimulatingmAbs to CD2 and CD28, we used a CD63 antibody thatwas
previously described to potently costimulate cytokine production and
proliferation in primary human T cells (Pﬁstershammer et al., 2004).
CD3 antibodies alone induced a modest upregulation of NF-κB, NFAT
and AP-1 reporter genes only when immobilized at a high concentration
(1 μg/ml). Thepresence of stimulating antibodies to CD28or CD2 strongly
costimulated the NF-κB, NFAT and AP-1 activity at all CD3 concentrations
tested. Interestingly, the CD63 antibody (mAb 11C9) was as effective in
inducing NF-κB, NFAT and AP-1 reporter activity as antibodies reactive
against CD28 or CD2 (Fig. 5 A–C).
Superagonistic CD28 antibodies have the capability to induce T cell
activation in absence of TCR-signals (Waibler et al., 2008). We tested
the capacity of a soluble CD28 superagonistic mAb to stimulate the
TPR cells. For comparison a stimulating CD3 mAb was also used. Both
agents induced similar levels of NF-κB and AP-1 activation but com-
pared to the CD3 mAb, the capacity of the superagonistic CD28 mAb
to induce NFAT activity was signiﬁcantly lower (Fig. 5 D).
3.6. Effect of 4-1BB costimulation on NF-κB, NFAT and AP-1 activity
Jurkat T cells are devoid of several costimulatory and coinhibitory re-
ceptors that play important roles in enhancing or attenuating responses
in primary T cells. We thus addressed whether our TPR cell system can
be utilized to study costimulators normally not expressed on Jurkat T
cells. One such molecule is 4-1BB, which acts as major costimulatory re-
ceptor in CD4 and CD8 T cells (Kober et al., 2008; DeBenedette et al.,
1997). We expressed 4-1BB in our TPR cells and used T cell stimulator
cells expressing 4-1BBL to trigger this receptor on the resultant reporters
(Fig. 6 A). Stimulation of TPR-4-1BB in presence of 4-1BBL signiﬁcantly
enhancedNF-κB and AP-1 activation,whereas NFAT activitywas even re-
duced. In addition, TCS-CD80 induced higher AP-1 activation than TCS-4-
1BBL indicating that CD80 is a stronger costimulator than 4-1BBL (Fig. 6
B–C, Suppl. Fig. 1 B). The presence of 4-1BBL on the TCS did not
costimulate control TPR cells not expressing 4-1BB (Suppl. Fig. 2 A).
3.7. Effect of PD-1 and BTLA signals on NF-κB, NFAT and AP-1 activity
In addition to activating costimulatory molecules, the response of T
cells is shaped by coinhibitory receptors that generate inhibitory intracel-
lular signalswhen engaged by their cognate ligands.We created TPR cells
expressing the well-established coinhibitory molecules PD-1 or BTLA to
quantitate their effect on NF-κB, NFAT and AP-1 activity. TCS expressing
high levels of PD-L1 or HVEMwere used to trigger PD-1 or BTLA, respec-
tively, in the reporter cells (Fig. 7 A, B). Coculture experiments revealed
that TPR-PD-1 cells exhibited strongly reduced NF-κB and NFAT activity
when stimulated with TCS expressing PD-L1 compared to control TCS.
(Fig. 7 C, E, Suppl. Fig. 1 D) Similar results were obtained for TPR-BTLA
stimulated in presence of HVEM (Fig 7 D, F, Suppl. Fig. 1 C). However,
we observed differences in the capacity of PD-1 and BTLA to down-
modulate the activity of the transcription factor AP-1:Whereas PD-1 en-
gagement resulted only in a slight non-signiﬁcant inhibition, the
presence of HVEM reduced AP-1-reporter activity in BTLA-expressing
Fig. 3. Effect of PMA, Ionomycin and Cyclosporin A on the transcription factor activity of NF-κB, NFAT and AP-1. A) Reporter assay to measure the effect of PMA and Ionomycin on the
transcription factor activity of NF-κB, NFAT and AP-1. TPR cells were stimulated with PMA, Ionomycin or PMA with Ionomycin (each at a ﬁnal concentration of 100 nM) for 24 h.
Summary of the normalized fold induction of gMFI of the TPR cells compared to unstimulated cells from ﬁve independent experiments of NF-κB, NFAT and AP-1 is shown. Statistics by
one-way ANOVA, followed by Tukey's multiple comparison post test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns: not signiﬁcant). B) Effect of different concentrations of Cyclosporin A on
NF-κB, NFAT and AP-1 during stimulation with TCS-CD80. Numbers show gMFI. Experiment shown is representative for six independently performed experiments. C) Comparison of
the effect of Cyclosporin A on signaling via CD2 and CD28 on NF-κB, NFAT and AP-1. Different concentrations of Cyclosporin A were used for TPR cells cocultivated with TCS-CD58 or
TCS-CD80. Mean and standard deviation (SD) of the normalized fold induction of gMFI of the TPR cells compared to unstimulated cells from six independent experiments of NF-κB,
NFAT and AP-1 are shown. Statistics by one-way ANOVA, followed by Tukey's multiple comparison post test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns: not signiﬁcant). D) Comparison of
the inhibitory effect of 200 μM Cyclosporin A on NF-κB and NFAT via CD2 and CD28. Inhibition is expressed as decrease of reporter induction in TPR cells stimulated with TCS-CD80 or
TCS-CD58 upon addition of CsA. NF-κB ***P = 0.0003 and NFAT ns P = 8990 (two-tailed paired t-test), TCS expressing CD80 compared to TCS expressing CD58.
15S. Jutz et al. / Journal of Immunological Methods 430 (2016) 10–20TPR cells signiﬁcantly. Antibodies to PD-L1 or HVEM fully blocked the in-
hibitory effects of these molecules on the TCS. PD-1 and BTLA are not en-
dogenously expressed on Jurkat cells and consequently control TCS and
PDL1 or HVEM expressing TCS induced similar level of NF-κB, NFAT and
AP-1 activity in the control TPR cells (Suppl. Fig. 2 B, C).4. Discussion
T cell activation and differentiation are processes governed by a
tightly regulated transcriptional network. It is well established that acti-
vation of NF-κB, NFAT and AP-1 drives proliferation and cytokine
Fig. 4. Knockdown of NF-κB1, NFATc3 or c-Fos and analysis of its effect on the transcription factor activity of NF-κB, NFAT and AP-1. A) Relative NF-κB1 mRNA expression in TPR cells
expressing NF-κB1 shRNA#1 or NF-κB1 shRNA#2 normalized to TPR cells expressing Ctrl shRNA. B) Reporter assay to investigate the effect of NF-κB1 knockdown on the transcription
factor activity of NF-κB, NFAT and AP-1. ShRNA was induced with 100 ng/ml doxycycline. TPR cells expressing NF-κB1 shRNA#1 or Ctrl shRNA were cocultivated with TCS-CD80.
Summary of the normalized fold induction of gMFI of NF-κB, NFAT and AP-1 reporter expression from ﬁve independent experiments is shown. Statistics by two-way ANOVA, followed
by Bonferroni post tests (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns P N 0.05). C) Relative NFATc3 mRNA expression in TPR cells expressing NFATc3 shRNA#1 or NFATc3 shRNA#2
normalized to TPR cells expressing Ctrl shRNA. D) Reporter assay to investigate the effect of NFATc3 knockdown on the transcription factor activity of NF-κB, NFAT and AP-1. ShRNA
expression was induced with 100 ng/ml doxycycline. TPR cells expressing NFATc3 shRNA#1, NFATc3 shRNA#2 or Ctrl shRNA were cocultivated with TCS-CD80. Summary of the
normalized fold induction of gMFI of NF-κB, NFAT and AP-1 reporter expression from seven independent experiments is shown. Statistics by two-way ANOVA, followed by Bonferroni
post tests (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns P N 0.05). E) Relative c-Fos mRNA expression in TPR cells expressing c-Fos shRNA#1 or c-Fos shRNA#2 normalized to TPR cells
expressing Ctrl shRNA. F) Reporter assay to investigate the effect of c-Fos knockdown on the transcription factor activity of NF-κB, NFAT and AP-1. ShRNA expression was induced with
100 ng/ml doxycycline. TPR cells expressing c-Fos shRNA#1, c-Fos shRNA#2 or Ctrl shRNA were cocultivated with TCS-CD80. Summary of the normalized fold induction of gMFI of NF-
κB, NFAT and AP-1 reporter expression from four independent experiments is shown. Statistics by two-way ANOVA, followed by Bonferroni post tests (**P ≤ 0.01; ***P ≤ 0.001; ns P N 0.05).
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study T cell signaling and the activation of transcription factors in re-
sponse to external stimuli (Abraham andWeiss, 2004). The availability
of ﬂuorescent proteins with non-overlapping emission spectraprompted us to develop a triple parameter Jurkat reporter, where re-
sponse elements for NF-κB, NFAT and AP-1 were coupled to CFP,
mCherry and GFP, respectively. We could demonstrate that reporter
gene induction is both a function of the strength and the quality of
Fig. 5. A) Effect of CD28, CD2 and CD63 antibodies on the transcription factor activity of
NF-κB, B) NFAT and C) AP-1. Different concentrations of aCD3 were used in combination
with isotype, CD28, CD2 and CD63 antibodies to stimulate the TPR cells. Experiment
shown is representative for six independently performed experiments. Mean and SD are
shown. Statistics of TPR cells stimulated with 1 μg/ml aCD3 by one-way ANOVA,
followed by Tukey's multiple comparison post test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001;
ns: not signiﬁcant). D) Effect of superagonistic CD28 antibody on NF-κB, NFAT and AP-1.
Summary of the normalized fold induction of gMFI of the TPR cells compared to
unstimulated cells from four independent experiments. Statistics by one-way ANOVA,
followed by Tukey's multiple comparison post test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns
P N 0.05).
17S. Jutz et al. / Journal of Immunological Methods 430 (2016) 10–20stimuli applied. Well-characterized agents were used to validate our
system: PMA potently stimulated NF-κB and AP-1 reporters and induc-
tion of theNFAT reporter was dependent on the presence of the calcium
ionophore Ionomycin. In agreement with published data we found that
only in the presence of PMA the addition of Ionomycin led to the full ac-
tivation of the NFAT reporter (Boss et al., 1996; Northrop et al., 1993;Wu et al., 1995). In line with well-established effects of CsA on NFAT
and NF-κB activity we observed that this calcineurin inhibitor strongly
inhibited NFAT reporter activity whereas NF-κB was affected to a
much lesser extent (Flanagan et al., 1991; Frantz et al., 1994). By con-
trast the immunosuppressive agent Rapamycin, which acts on the
mTor pathway (Ballou and Lin, 2008) had no signiﬁcant effect on the re-
porter activity (data not shown). This was also observed with single re-
porter cells carrying responsive elements for NFAT, NF-κB or AP-1
controlling the expression of eGFP (Ratzinger et al., 2014). In addition,
the speciﬁcity of the constructs used in our reporter cells was corrobo-
rated by shRNA-mediated knockdown of NFATc3, NF-κB and c-Fos
expression.
We have previously devised a system termed T cell stimulators (TCS)
to activate human T cells in the presence of costimulatory ligands of
choice. Here we have used the TCS to study the effects of costimulatory
signals on the NF-κB, NFAT and AP-1 reporter gene expression. We
show that engagement of the primary costimulatory receptor CD28 by
CD80 potently enhances induction of all three reporters. CD2 signals trig-
gered through CD58 expressing TCS have previously been shown to gen-
erate potent activating signals in human T cells (Leitner et al., 2010b;
Leitner et al., 2015) and in linewith these results strong reporter gene ex-
pression was induced by this costimulatory pathway. However CD2 sig-
nals are less potent than CD28 signals and the lower stimulatory
capacity of this costimulatory pathwaywas reﬂected by a signiﬁcantly re-
duced upregulation of NF-κB reporter activity. T cells receiving CD28 sig-
nals are less sensitive to CsA inhibition (Hess and Bright, 1991; June et al.,
1987) and we have previously shown that the proliferation of primary
human T cells stimulated in the presence of CD80 is less sensitive to CsA
inhibition than T cells stimulated by CD58 (Leitner et al., 2011). In our re-
porter assays we found that CsA treatment differentially affected NF-κB
activity but not NFAT activity in CD28 and CD2 costimulated TPR cells.
Thus, it is possible that the lower sensitivity of CD28-costimulated T
cells towards CsA is a result of a reduced capacity of CsA to inhibit NF-
κB in presence of CD28 signals.
Immobilized agonistic or soluble mAb are widely used to trigger
costimulatory receptors on T cells and they are essential tools for func-
tional studies on surface receptors for which no natural ligands have
been described. We have previously reported on a mAb designated
11C9 that is equally potent as agonistic CD28mAb to costimulate prolif-
eration and cytokine production in anti-CD3 activated primary human T
cells (Pﬁstershammer et al., 2004). The antigen targeted by this mAb
was subsequently identiﬁed as CD63 andwe have found that the potent
costimulatory properties are a unique feature of clone 11C9 as they
were not observed with other CD63 mAb. Here we have compared
this mAb with CD2 and CD28 mAb regarding its capability
to costimulate reporter gene expression in our TPR cells when
coimmobilized with anti-CD3 mAb. In line with our previous results
that describe potent costimulation via clone 11C9 we have observed
that triggering CD63 can enhance NF-κB, NFAT and AP-1 activity as efﬁ-
cient as ligation of the costimulatory receptors CD2 or CD28 with ago-
nistic antibodies. These experiments indicate that the TPR cells are
equally suited to detect signals generated upon interaction of natural li-
gands or agonistic antibodies with costimulatory receptors expressed
on the Jurkat T cell line.
However Jurkat cells express a limited set of costimulatory receptors
and it was of interest to determine whether cosignaling molecules are
functional when expressed on the TPR cells. To this end we have
expressed activating (4-1BB) as well as inhibitory (PD-1 and BTLA)
cosignalingmolecules on the TPR cells and used T cell stimulator cells ex-
pressing their ligands to trigger these receptors along with the TCR-
complex. We found that 4-1BB signals strongly upregulated NF-κB and
AP-1 activity. In contrast, NFAT transcription factor activity decreased
upon signaling via 4-1BB. Thismay be due to the fact that 4-1BB signaling
is mediated by TRAF2, which in turn is described to inhibit NFAT-
mediated transcription via NFAT-interacting protein (NIP45) (Lieberson
et al., 2001; Saoulli et al., 1998). It is generally accepted that CD28 is a
Fig. 6. Effect of signaling via 4-1BB on the transcription factor activity of NF-κB, NFAT and AP-1. A) FACS analysis of the expression of surface molecules on TCS and TPR cells. Open
histograms: control cells; ﬁlled histograms: TCS or TPR cells expressing the respective molecules. B) Reporter assay to investigate the effect of signaling via 4-1BB on the transcription
factor activity of NF-κB, NFAT and AP-1. TPR cells expressing 4-1BB were cocultivated with TCS coexpressing 4-1BBL for 24 h. Activation of NF-κB, NFAT and AP-1 was measured by
FACS analysis. Numbers show gMFI. Experiment shown is representative for eleven independently performed experiments. C) Summary of the normalized fold induction of gMFI of
the TPR cells compared to unstimulated cells from eleven independent experiments. Statistics by one-way ANOVA, followed by Tukey's multiple comparison post test (*P ≤ 0.05;
***P ≤ 0.001; ns P N 0.05).
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expressing CD80 induced higher proliferation in primary human T cells
than TCS expressing 4-1BBL (Leitner et al., 2010b; Kober et al., 2008). In
line with these results we observed stronger upregulation of reporter
gene expression in TPR cells stimulated via CD28 than via 4-1BB. More-
over, we have observed that ligation of the coinhibitory receptors PD-1
and BTLA on the TPR cells resulted in a strong downregulation of NF-κB
and NFAT whereas BTLA signals were more potent in reducing AP-1 ac-
tivity. Thus also molecules not naturally expressed in Jurkat cells can be
studied regarding their capacity to induce or attenuate the activity of
the transcription factors NF-κB, NFAT or AP-1 when introduced into the
TPR cells. Absence of receptors of interest even offers additional possibil-
ities e.g. to introduce receptorswithmutated cytoplasmic domains to dis-
sect the intracellular motifs that are critically involved in the generation
of activating or inhibitory signals upon receptor engagement. TCS are
well suited to provide costimulatory signals to the TPR cells since they
display costimulatory ligands in the context of a cell surface and thus
allow for a “natural” receptor–ligand interaction. We found that the
TCS-TPR system is a sensitive tool to detect the effects of antibodies,
which were previously described to block inhibitory pathways (Brown
et al., 2003; Peretz et al., 2012; Leitner et al., 2013). Interfering with T
cell inhibitory pathways has already been demonstrated to efﬁciently in-
crease the anti-tumor response in cancer patients (Hamid et al., 2013;
Hodi et al., 2010). Consequently, there are currently intense efforts to tar-
get so-called checkpoint inhibitors for the treatment of melanoma pa-
tients but also for the therapy of other malignancies (Buchbinder and
McDermott, 2015; Johnson et al., 2015). In addition to established path-
ways engaging CTLA-4 or PD-1 such efforts are focusing on emerging
pathways like BTLA, TIGIT or 2B4 (CD244) (Pauken and Wherry, 2014;
Pardoll, 2012). Our preliminary data indicate that these molecules are
functional when introduced in the Jurkat T cell line (Fig. 6 and data not
shown). Currently, the biology of most of these novel checkpoint inhibi-
tors is not fully understood. TPR cells in conjunction with TCS can be
used as a versatile platform to investigate the impact of such inhibitory
pathways on the activation of NF-κB, NFAT or AP-1 in a well-controlledreductionist system. Keeping limitations of studies with transformed T
cell lines in mind such studies should be complemented with studies
on primary T cells, including T cells that display an exhausted phenotype.
Moreover, the TPR cells in conjunctionwith TCSmight be especially valu-
able for pre-assessing antibodies regarding their ability to efﬁciently in-
terfere with T cell coinhibitory pathways. They can be used to screen
panels of antibodies to coinhibitory ligands or receptors to identify the
most promising candidate reagents for proﬁling in more complex and
time consuming assays with primary T cells.
Although the experiments performed in this study focus on the use
of the TPR cells to study T cell costimulation, the utility of these cells is
obviously not limited to such applications. They could f.i. be used to pro-
ﬁle immunosuppressive compounds regarding their effects on NF-κB,
NFAT and AP-1 activation in T cell activation or improve chimeric anti-
gen receptor (CAR) design.
T cells armedwith chimeric antigen receptors “CARs” that target sur-
face molecules expressed on leukemias or other cancers have great po-
tential to ﬁght malignant cells when adoptively transferred into cancer
patients (Turtle et al., 2012; Cheadle et al., 2014). There are continuous
efforts to equip CARswith signaling domains that endow themwith im-
proved responsiveness and effector function towards cells harboring
their target antigens. In this context TPR cells might be an exquisite
tool to identify signaling domains that potently activate NF-κB, NFAT
and AP-1 and thus might result in improved functionality of the
resulting CAR molecules.
In conclusion, our results illustrate the usefulness of ﬂuorescent pro-
tein based triple parameter reporter cells to gain a better insight in the
transcriptional network that drives cellular activation. In conjunction
with TCS, the Jurkat TPR cells allow to study virtually all T cell
costimulatory and coinhibitory pathways regarding their impact on
NF-κB, NFAT and AP-1 activity. In addition, the TPR cells are an effective
tool for the identiﬁcation and characterization of agents that enhance or
suppress T cell activation processes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jim.2016.01.007.
Fig. 7. Effect of signaling via PD-1 and BTLA on the transcription factor activity of NF-κB, NFAT and AP-1. A, B) FACS analysis of the expression of surface molecules on TCS and TPR cells.
Open histograms: control cells; ﬁlled histograms: TCS or TPR cells expressing the respectivemolecules. C) Reporter assay to investigate the effect of signaling via PD-1 on the transcription
factor activity of NF-κB, NFAT and AP-1. TPR cells expressing PD-1 were cocultivated with TCS coexpressing PD-L1. Anti-PD-L1 and isotype control antibody were used at a ﬁnal
concentration of 5 μg/ml. Activation of NF-κB, NFAT and AP-1 was analyzed by FACS. Numbers show gMFI. Experiment shown is representative for seven independently performed
experiments. D) Reporter assay to investigate the effect of signaling via BTLA on the transcription factor activity of NF-κB, NFAT and AP-1. TPR cells expressing BTLA were cocultivated
with TCS expressing HVEM. Anti-HVEM and isotype control antibody were used at a ﬁnal concentration of 5 μg/ml. Activation of NF-κB, NFAT and AP-1 was analyzed by FACS.
Numbers show gMFI. Experiment shown is representative for four independently performed experiments. E) Summary of the normalized fold induction of gMFI of the TPR cells
compared to unstimulated cells from seven independent experiments. NF-κB, NFAT and AP-1. Statistics by one-way ANOVA, followed by Tukey's multiple comparison post test
(*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns P N 0.05). F) Summary of the normalized fold induction of gMFI of the TPR cells compared to unstimulated cells from four independent
experiments of NF-κB, NFAT and AP-1. Statistics by one-way ANOVA, followed by Tukey's multiple comparison post test (**P ≤ 0.01; ***P ≤ 0.001; ns P N 0.05).
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